Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment
Related Experiment Videos
1Department of Cardiology, University Hospital of Nancy, France.
Insights
Secondary aldosteronism worsens congestive heart failure (CHF) outcomes. Combining ACE inhibitors with spironolactone may improve treatment by more fully inhibiting the renin-angiotensin-aldosterone system (RAAS) without serious side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Secondary aldosteronism negatively impacts congestive heart failure (CHF) patients, increasing mortality.
- Elevated aldosterone levels correlate with CHF progression due to renin-angiotensin-aldosterone system (RAAS) activation, exacerbated by diuretics.
- Angiotensin-converting enzyme (ACE) inhibitors offer limited and transient aldosterone reduction.
Purpose of the Study:
- To evaluate the potential benefits and safety of combining ACE inhibitors with spironolactone in CHF patients.
- To explore if this combination provides additive benefits beyond ACE inhibitors alone.
Main Methods:
- Review of existing studies and clinical reports on the combination therapy.
- Analysis of data from the CONSENSUS trial regarding safety parameters like potassium and creatinine levels.
Main Results:
- Spironolactone, an aldosterone antagonist, may offer independent and additive effects to ACE inhibitors.
- Emerging evidence suggests spironolactone has direct cardiac and vascular benefits.
- Limited data suggests combining ACE inhibitors and spironolactone may lead to clinical improvement without significant adverse effects.
Conclusions:
- Combining ACE inhibitors and spironolactone may offer a more complete RAAS inhibition and potential clinical benefits in CHF.
- Further prospective studies are needed to confirm the efficacy and safety of this combination therapy.
Abstract:
Secondary aldosteronism has deleterious effects in patients with congestive heart failure (CHF) and can contribute to congestion, ventricular arrhythmias, and sudden death. Mortality is higher in patients with elevated levels of plasma aldosterone. Aldosterone increases as CHF progresses as a result of activation of the renin-angiotensin-aldosterone system (RAAS). This is further amplified by the routine use of diuretics. Angiotensin-converting enzyme (ACE) inhibitors produce a profound and consistent inhibition of angiotensin II production, but they exert only a mild and transient antialdosterone effect. In a number of studies involving ACE inhibitors, plasma aldosterone levels at the end of the trial do not differ significantly from baseline. Spironolactone, a specific aldosterone receptor antagonist, may exert an independent and additive effect to that of ACE inhibitors. Apart from its renal effects, recent evidence suggests that spironolactone may exert direct cardiac and vascular effects inhibiting cardiac collagen hypertrophy and limiting vascular constriction. Combining an ACE inhibitor and spironolactone may achieve a more complete inhibition of the whole RAAS and may produce further clinical benefits. The efficacy and safety of such a combination has not been properly addressed. In the CONSENSUS trial, plasma potassium and creatinine levels were not necessarily adversely affected when enalapril was added to the regimens of patients receiving spironolactone, a condition existing in > 40% of the patients enrolled in this study. One prospective open study and other anecdotal reports suggest that combining spironolactone and ACE inhibitors resulted in clinical improvement without serious side effects in patients who could not tolerate further increases in the ACE inhibitor dose.(ABSTRACT TRUNCATED AT 250 WORDS)